**Author details**

Benjamin Wadowski, David T. Severson, Raphael Bueno and Assunta De Rienzo\* The Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program, Division of Thoracic Surgery and the Lung Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

\*Address all correspondence to: aderienzo@bwh.harvard.edu

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**101**

*Genetic Alterations of Malignant Pleural Mesothelima DOI: http://dx.doi.org/10.5772/intechopen.93756*

> loss of heterozygosity analyses identify a common region of deletion at 15q11.1- 15 in human malignant mesothelioma. Cancer Research. 1999;**59**(2):450-454

[12] De Rienzo A, Jhanwar SC, Testa JR. Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma. Genes, Chromosomes &

[13] Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nature

[14] Guo G, Chmielecki J, Goparaju C, et al. Whole-exome sequencing reveals frequent genetic alterations in *BAP1*, *NF2*, *CDKN2A*, and CUL1 in malignant pleural mesothelioma. Cancer Research.

[11] De Rienzo A, Balsara BR, Apostolou S, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene. 2001;**20**(43):6245-6249

Cancer. 2000;**28**(3):337-341

Genetics. 2016;**48**(4):407-416

[15] Hmeljak J, Sanchez-Vega F,

[16] Zhang J, Chiodini R, Badr A, Zhang G. The impact of nextgeneration sequencing on genomics. Journal of Genetics and Genomics.

[17] Sugarbaker DJ, Richards WG, Gordon GJ, et al. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proceedings of the National Academy of Sciences of the United States of America.

Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discovery.

2015;**75**(2):264-269

2018;**8**(12):1548-1565

2011;**38**(3):95-109

2008;**105**(9):3521-3526

[1] Robinson BW, Lake RA. Advances in malignant mesothelioma. The New England Journal of Medicine.

[2] Henley SJ, Larson TC, Wu M, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. International Journal of Occupational and Environmental

[3] Raja S, Murthy SC, Mason DP. Malignant pleural mesothelioma. Current Oncology Reports.

[4] Sugarbaker DJ, Wolf AS, Chirieac LR, et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following

extrapleural pneumonectomy. European Journal of Cardio-Thoracic Surgery.

[6] Prazakova S, Thomas PS, Sandrini A, Yates DH. Asbestos and the lung in the 21st century: An update. The Clinical Respiratory Journal. 2014;**8**(1):1-10

[5] Bianchi C, Bianchi T. Malignant mesothelioma: Global incidence and relationship with asbestos. Industrial

Health. 2007;**45**(3):379-387

[7] Mutsaers SE. The mesothelial cell. The International Journal of Biochemistry & Cell Biology.

[8] Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Seminars in Oncology. 2002;**29**(1):2-17

[9] Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma (review). International Journal of Oncology. 1999;**14**(1):181-188

[10] Balsara BR, Bell DW, Sonoda G, et al. Comparative genomic hybridization and

2004;**36**(1):9-16

**References**

2005;**353**(15):1591-1603

Health. 2013;**19**(1):1-10

2011;**13**(4):259-264

2011;**40**(2):298-303

*Genetic Alterations of Malignant Pleural Mesothelima DOI: http://dx.doi.org/10.5772/intechopen.93756*
